Earlier studies have revealed that (i) hepatitis B virus (HBV) core protein (HBV-CP) is a 21 kDa phosphoprotein (185 amino acid residues) in intact cells 1) ; (ii) the arginine (Arg)-rich C-terminal region (positions 157-185) on HBV-CP contains potent phosphorylation sites for several intracellular protein kinases, 2) such as cAMP-dependent protein kinase (PKA), Ca 2ϩ -dependent protein kinase (PKC), cyclindependent protein kinase Cdc2 and serine (S)/arginine (R) protein-specific kinase; and (iii) the phosphorylation of HBV-CP by these protein kinases is implicated in promoting DNA replication of HBV and is critical for subsequent pregenomic RNA packaging.
; (ii) the arginine (Arg)-rich C-terminal region (positions 157-185) on HBV-CP contains potent phosphorylation sites for several intracellular protein kinases, 2) such as cAMP-dependent protein kinase (PKA), Ca 2ϩ -dependent protein kinase (PKC), cyclindependent protein kinase Cdc2 and serine (S)/arginine (R) protein-specific kinase; and (iii) the phosphorylation of HBV-CP by these protein kinases is implicated in promoting DNA replication of HBV and is critical for subsequent pregenomic RNA packaging. [2] [3] [4] [5] These earlier studies suggest that the selective inhibition of HBV-CP phosphorylation by potent protein kinase inhibitors may be involved in the prevention of viral multiplication in HBV-infected cells.
In our preliminary experiments, at least four sulfated compounds [suramin (a compound with six sulfo groups, Fig. 1A ) in vitro. These preliminary results suggested that suramin may interact in vitro with the positively charged Arg-rich C-terminal region, containing potent phosphorylation sites for PKA and PKC, on HBV-CP in vitro. It has been reported that (i) suramin inhibits PKAIIa (IC 50 ϭapprox. 0.66 mM) much less potently than type I PKC (IC 50 ϭapprox. 29 mM) using histone III-S as a phosphate acceptor in vitro 6) ; and (ii) suramin also inhibits reverse transcriptase of human immunodeficiency virus type 1 (HIV-1) in vitro 7) and Trypanosoma malate dehydrogenase in vivo. 8) Furthermore, it has been demonstrated that (i) suramin acts as an potent inhibitor for core protein-associated two enzyme activities (reverse transcriptase and DNA polymerase) of duck hepatitis B virus (DHBV) in vitro 9) ; and (ii) the drug effectively blocks the early stages of DHBV infection in cultured cells. 10) However, the suramin-induced inhibitory mechanism involved in the viral replication in DHBV-or HBV-infected cells remains to be elucidated, and there are no reports concerning the inhibitory effect of suramin on the PKAIIa-mediated phosphorylation of HBV-CP in vitro. Therefore, the present study was undertaken to (i) further characterize suramin as a selective inhibitor for the phosphorylation of HBV-CP by two PKAs (PKAIa and PKAIIa) using three GST-Hcore fusion polypeptides (GST-Hcore, Hcore157B and Hcore164B) in vitro; (ii) detect the direct binding of suramin to the Arg-rich C-terminal region between 157 and 185 of HBV-CP; and (iii) determine the inhibitory kinetics of suramin on the PKAIIa-mediated phosphorylation of Hcore157B in vitro. 11) was a generous gift from Dr. Tanaka (Nagasaki University, Japan).
MATERIALS AND METHODS

Chemicals and Reagents
Preparation of GST-Hcore and Two GST-Hcore Fusion Polypeptides The HBV core sequences were amplified from HBV DNA and their nucleotide sequences were identified by polymerase chain reaction (PCR) using 5Ј and 3Ј primers bearing BamHI and XhoI sites, respectively. 12) PCR products were cleaved and ligated into the BamHI-XhoI site between glutathione-S-transferase (GST) and the chitin-binding domain (CBD) of pGST-CBD plasmid DNA, which expresses a GST fusion protein in Escherichia coli under the control of isopropyl-b-D-thiogalacto-pyranoside (IPTG)-inducible promoter. Expression and purification of these fusion proteins (GST-Hcore, Hcore157B and Hcore164B) were carried out as described by Kuroki et al. 13) Plasmids were used to transform competent Rosetta cells, and the IPTG-induced cultured cells were lysed by sonication. These extracts were applied onto a glutathione-sepharose column and the bound GST fusion proteins on the affinity-column were eluted separately with 50 mM Tris-HCl (pH 8.0) containing 20 mM reduced glutathione.
Detection of 32 P-Phosphorylated Polypeptides by SDS-PAGE Followed by Autoradiography To detect GSTHcore, Hcore157B, Hcore164B, protamine 1B, protamine sulfate or histone H2B (approx. 5 mg each) phosphorylated by PKAIIa or PKAIa (approx. 50 ng) in vitro, reaction mixtures (total 50 ml) comprising 40 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM Mn 2ϩ , 1 mM cAMP and 5 mM [g- 32 P-Labeled polypeptides in the reaction mixtures were detected by sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by autoradiography, as described in our previous paper.
14)
Assay for the Phosphorylation of Hcore157B by Two PKAs (PKAIa a and PKAIIa a) in Vitro The phosphorylation of Hcore157B by two PKAs (PKAIa and PKAIIa) was determined in vitro. After incubation for 30 min at 30°C, the phosphorylation of Hcore157B by two PKAs was arrested by the addition of 0.5 ml 20% trichloroacetic acid (TCA) and 0.25 ml 0.1 M sodium pyrophosphate containing bovine serum albumin (approx. 1 mg/ml) and 10 mM EDTA. The TCA-insoluble precipitates were trapped on a glass membrane filter (Advantec GF/75, Tokyo, Japan), and then washed successively with 2% TCA and 100% ethanol. After drying, the 32 P-radioactivity on the membrane filter was measured with a liquid scintillation spectrometer, as stated in our previous report. 11, 14) Measurement of the Binding-Affinity of Suramin in Vitro by Using a QCM The binding affinities of suramin and CH-3S with GST-Hcore, Hcore157B, protamine 1B, histone H2B or GST were measured by using a quartz crystal microbalance (QCM, Initium, Tokyo, Japan), as described originally by Sun et al. 15) GST-HBV-CP, Hcore157B, protamine 1B, histone H2B or GST (approx. 2 mg each) was directly immobilized on a QCM plate in 8 ml of 40 mM TrisHCl (pH 7.6) at 25°C until an equilibrium was attained. The indicated concentrations of suramin or CH-3S were added to the equilibrated solution. The resonance frequency of the QCM was defined as the 0 position after equilibrium. The frequency change in the QCM responding to GST-Hcore, Hcore157B, protamine 1B, histone H2B or GST was recorded for specific time points. The stability of the 27-MHz QCM frequency in the solution was 5 Hz for 12 h at 25°C.
RESULTS
Phosphorylation of GST-Hcore Fusion Polypeptides by Two PKAs in Vitro
To detect the phosphorylation of GSTHcore and two GST-Hcore fusion polypeptides (Hcore157B and Hcore164B) by two PKAs (PKAIa and PKAIIa) in vitro, these three polypeptides (approx. 5 mg each) were separately incubated for 30 min at 30°C with PKAIIa and 5 mM [g-32 P]ATP (500 cpm/pmol) in the presence or absence of 1 mM cAMP. Figure 2A shows that (i) PKAIIa phosphorylates GST-Hcore in vitro (lane 2); and (ii) this phosphorylation is significantly stimulated by 1 mM cAMP (lane 3), but completely inhibited by 1 mM GP (lane 4, Fig. 2A ). Under the same experimental conditions, both Hcore157B (lane 2) and Hcore164B (lane 3, Fig. 2B ) were highly phosphorylated by PKAIIa in the presence of 1 mM cAMP in vitro. No difference in the PKAIIa-mediated phosphorylation kinetics between Hcore157B and Hcore164B in the presence of 1 mM cAMP in vitro was observed (Fig. 2C) . Similar phosphorylation of Hcore157B as well as Hcore164B by PKAIa instead of PKAIIa was observed in vitro (data not shown). However, no phosphorylation of recombinant GST by these two PKAs (PKAIa and PKAIIa) in vitro was detected. Only phosphoserine was detected in Hcore157B, containing Ser-170 and Ser-178, and GST-Hcore phosphorylated by two PKAs in the presence of 1 mM cAMP in vitro (data not shown).
The Inhibitory Effects of Five Sulfated Compounds on the PKAIIa a-Mediated Phosphorylation of Hcore157B in Vitro The inhibitory effects of five sulfated compounds [suramin, NF449 (a derivative of suramin), Evans blue, CH-3S and fucoidan] on the phosphorylation of Hcore157B by PKAIIa were compared in vitro. Figure 3A shows that (i) suramin is the most effective inhibitor of the PKAIIa-mediated phosphorylation of Hcore157B among the five tested compounds; and (ii) the IC 50 of suramin (approx. 10 nM) is approx. 5-fold lower than that of Evans blue (IC 50 ϭapprox. 50 nM), approx. 7-fold lower than that of NF449 (IC 50 ϭap-prox. 70 nM), approx. 10-fold lower than that of CH-3S (IC 50 ϭapprox. 0.1 mM) and approx. 20-fold lower than that of fucoidan (IC 50 ϭapprox. 0.2 mM).
The inhibitory effects of suramin on the PKAIIa-mediated phosphorylation of five distinct substrates (GST-Hcore, Hcore157B, protamine 1B, protamine sulfate and histone H2B) were determined in vitro. The PKAIIa-mediated phosphorylation of GST-Hcore and Hcore157B was inhibited by suramin in a dose-dependent manner in vitro (Fig. 3B ). There were similar suramin-induced inhibitory kinetics in the PKAIIa-mediated phosphorylation between GST-Hcore and Hcore157B (Fig. 3B) . In contrast, higher concentrations of suramin were required to inhibit the PKAIIa-mediated phosphorylation of protamine 1B (IC 50 ϭapprox. 0.2 mM), protamine sulfate (IC 50 ϭapprox. 1.0 mM), and histone H2B (IC 50 ϭ approx. 0.4 mM, Fig. 3B ). There was approx. 40-fold dosediscrepancy in the suramin-induced inhibition of the PKAIIa-mediated phosphorylation between Hcore157B and histone H2B in vitro. The IC 50 of suramin on the autophosphorylation of PKAIIa was approx. 0.7 mM, which were approx. 70-fold higher than that observed with the PKAIIamediated phosphorylation of Hcore157B in vitro (Fig. 3C) . The IC 50 of suramin on the PKC-mediated phosphorylation of Hcore157B was found to be approx. 50 nM, which was approx. 5-fold higher than its effect on the PKAIIa-mediated phosphorylation of Hcore157B in vitro (Fig. 4) . These results suggest that suramin (i) may inhibit the PKA-mediated phosphorylation of GST-Hcore as well as Hcore157B through its direct binding to their Arg-rich domains (positions 157- Inhibitory Kinetics of Suramin on the PKAIIa a-Mediated Phosphorylation of Hcore157B in Vitro The inhibitory kinetics of suramin on the PKAIIa-mediated phosphorylation of Hcore157B was determined in vitro. An apparent K m of PKAIIa for Hcore157B shifted from 0.08 to 0.18 mg/ml when incubated with 30 nM suramin, whereas the V max of Hcore157B shifted from 0.57 to 0.56 nmol/mg/min in the presence of 30 nM suramin (Fig. 5) . Under the same experimental conditions, similar results were obtained with PKAIa instead of PKAIIa in vitro (data not shown). These results show that direct binding of suramin to Hcore157B reduces its affinity for two PKAs (PKAIa and PKAIIa) in vitro.
The High Binding Affinity of Suramin for Hcore157B in Vitro The binding affinities of suramin with GST-Hcore, Hcore157B, protamine 1B, histone H2B and GST were determined in vitro by using a QCM. As expected, suramin directly bound to GST-Hcore, Hcore157B and protamine 1B with different affinities, but did not bind to GST in vitro (Fig.  6A) . The higher binding affinity of suramin with Hcore157B was observed, but not significantly with histone H2B (Fig.   6A ). In contrast, the binding affinity of CH-3S with these basic proteins was compared in vitro. The binding affinity of CH-3S to these three basic proteins (GST-Hcore, Hcore157B and protamine 1B) was approx. 2-fold higher than that observed with suramin in vitro (Fig. 6B) . The significant binding affinity of CH-3S with histone H2B was observed (Fig.  6B) . These results show that (i) suramin has a higher binding affinity for Hcore157B in comparison with that observed for protamine 1B in vitro; and (ii) both suramin and CH-3S may prevent the phosphorylation of Hcore157B by two PKAs through their direct binding to the near phosphorylation sites for two PKAs on these substrate proteins in vitro.
DISCUSSION
In the present study, the inhibitory effect of suramin on the phosphorylation of GST-Hcore and two GST-Hcore fusion polypeptides (Hcore157B and Hcore164B) by two PKAs (PKAIa and PKAIIa) was biochemically investigated in vitro. It was found that (i) PKAIIa highly phosphorylated GST-Hcore, Hcore157B as well as Hcore164B in the presence of 1 mM cAMP in vitro ( Figs. 2A and 2B) ; (ii), in the presence of 1 mM cAMP, both Hcore157B and Hcore164B, containing Ser-170 and Ser-178, were phosphorylated timedependently by PKAIIa in a similar kinetic in vitro (Fig.  2C) ; (iii) this phosphorylation was inhibited by suramin in a dose-dependent manner (Fig. 3A) ; and (iv) the IC 50 (approx. 10 nM) of suramin on the PKAIIa-mediated phosphorylation of Hcore157B was significantly lower than those determined with other substrates, such as protamine 1B, protamine sulfate and histone H2B in vitro (Fig. 3B) .
The inhibitory effect of suramin on the PKAIIa-mediated phosphorylation of Hcore157B did not correspond to the sulfate number of the sulfated inhibitors, because (as shown in (B) The Binding Affinities of CH-3S with GST, GST-Hcore, Hcore157B, Protamine 1B or Histone H2B in Vitro
The binding affinities of CH-3S with these polypeptides (approx. 2 mg each) were examined, under the same experimental conditions as in (A). CH-3S (final concentration: Fig. 3A) the PKAIIa-mediated phosphorylation of Hcore157B was significantly more sensitive to suramin than NF449, which contains eight sulfates. The IC 50 (approx. 0.7 mM) of suramin on the autophosphorylation of PKAIIa was about 70-fold higher than that observed for the PKAIIa-mediated phosphorylation of Hcore157B in vitro (Fig. 3C) . In contrast, the IC 50 (approx. 10 nM) of suramin on the PKAIIa-mediated phosphorylation of Hcore157B was approx. 5-fold lower than that (approx. 50 nM) determined with the phosphorylation of Hcore157B by PKC in vitro (Fig. 4) . In addition, inhibitory kinetic experiments (Fig. 5) revealed that direct binding of suramin to Hcore157B significantly reduced the binding affinity of the protein substrate for PKAIIa in vitro.
Suramin may directly bind to the near two potential phosphorylation sites (Ser-170 and Ser-178) for PKA on the Argrich C-terminal region at positions between 164 and 185 (protamine-like sequence) of HBV-CP, thus selectively preventing the phosphorylation of HBV-CP by two PKAs (PKAIa and PKAIIa) in vitro. This speculation is supported by the in vitro experimental results that (i) two PKAs (PKAIa and PKAIIa) phosphorylate only Ser-residues on Hcore157B as well as Hcore164B (Fig. 2B); (ii) the PKAmediated phosphorylation of Hcore157B is more sensitive to suramin than the phosphorylation of Hcore157B by PKC (Fig. 4) ; and (iii) suramin has a high binding affinity for Hcore157B, but not for histone H2B (Fig. 6A) . The direct binding of suramin to the Arg-rich C-terminal region on HBV-CP is similar to the observations reported for the binding sites of suramin on human neutrophil elastase, ryanodine receptor (RYR1) and cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel. [16] [17] [18] Mely et al. reported that suramin strongly binds to six Arg-residues on human neutrophil elastase, which is a 30 kDa glycoprotein belonging to the class of serine proteinases. 16) Furthermore, it has been reported that suramin interacts with the calmodulin binding sites on the ryanodine recepter (RYR1) 17) as well as CFTR for chloride channel. 18) There is a structural similarity in the Arg-rich domains, containing glutamine (Glu)-residues beside two potential phosphorylation sites for PKA among these three suramin-binding proteins (neutrophil elastase, RYR1 and CFTR) and Hcore164B (positions 164-185, Fig. 1A ). However, there are no Glu-residues in the Arg-rich amino acid domains on protamine 1B. These structural differences of the suramin-binding domains between HBV-CP and protamine 1B may be one reason why they exhibit different substrate activities for two PKAs (PKAIa and PKAIIa) in vitro. Therefore, it seems likely that the Arg-rich regions (positions 164-185), containing Glu-169 and Glu-179, on HBV-CP may include the potent binding sites for suramin in vitro.
To clearly understand the physiological effect of suramin on the PKA-mediated phosphorylation of HBV-CP, further analytical studies will be required to: (i) detect the selective inhibition of suramin on the growth of HBV through its direct physiological interaction with HBV-CP and the suramin sensitivity to the PKA-mediated phosphorylation of HBV-CP in virus-infected cells; and (ii) determine the critical suramin-binding sites on HBV-CP.
